| 1 |
Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 2 |
Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo S. Tissue Distribution of Suvorexant in Three Forensic Autopsy Cases. Journal of Analytical Toxicology 2018;42:276-83. [DOI: 10.1093/jat/bkx110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 3 |
Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 4 |
Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, Croft M, van Gerven J, Krähenbühl S, Dingemanse J. Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry. CDM 2019;20:254-65. [DOI: 10.2174/1389200220666190206141814] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 5 |
Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. [PMID: 27471419 DOI: 10.2147/nss.s76910] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 6 |
Sullinger S, Bryand K, Kerrigan S. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS). J Anal Toxicol 2017;41:224-9. [PMID: 28035034 DOI: 10.1093/jat/bkw132] [Reference Citation Analysis]
|
| 7 |
Yee KL, Mccrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig 2018;38:631-8. [DOI: 10.1007/s40261-018-0650-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Boof M, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol 2019;75:195-205. [DOI: 10.1007/s00228-018-2559-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Landolt HP, Holst SC, Valomon A. Clinical and Experimental Human Sleep-Wake Pharmacogenetics. Handb Exp Pharmacol 2019;253:207-41. [PMID: 30443785 DOI: 10.1007/164_2018_175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 11 |
Landry I, Aluri J, Hall N, Filippov G, Dayal S, Moline M, Reyderman L. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacol Res Perspect 2021;9:e00734. [PMID: 33689224 DOI: 10.1002/prp2.734] [Reference Citation Analysis]
|
| 12 |
Rajana N, Devi DR, Kumar Reddy DN, Babu JM, Basavaiah K, Balakumaran K. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC. J Chromatogr Sci 2020;58:433-44. [PMID: 32134104 DOI: 10.1093/chromsci/bmaa003] [Reference Citation Analysis]
|
| 13 |
Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017;86:181-92. [PMID: 28279667 DOI: 10.1016/j.yrtph.2017.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 14 |
Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F. The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J Pharmacol Exp Ther 2017;362:489-503. [DOI: 10.1124/jpet.117.241596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 15 |
Skillman B, Kerrigan S. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int 2020;312:110307. [PMID: 32473525 DOI: 10.1016/j.forsciint.2020.110307] [Reference Citation Analysis]
|
| 16 |
Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 17 |
Iqbal M, Ezzeldin E, Khalil NY, Alam P, Al-rashood KA. UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets. Journal of Pharmaceutical and Biomedical Analysis 2019;164:1-8. [DOI: 10.1016/j.jpba.2018.10.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
|
